Gelation Embolism Agents Suppress Clinical TACE-incited Pro-metastatic Microenvironment Against Hepatocellular Carcinoma Progression

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2024 Oct 30

PMID 39476535

Authors

Li Song

Chunyan Zhu

Qing Shi

Yuhan Xia

Xiayi Liang

Wen Qin

Tao Ye

Biwei Yang

Xin Cao

Jinglin Xia

Kun Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Current embolic agents in transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) encounter instability and easy leakage, discounting TACE efficacy with residual HCC. Moreover, clinical TACE aggravates hypoxia and pro-metastatic microenvironments, rendering patients with HCC poor prognosis.

Methods: Herein, we developed Zein-based embolic agents that harness water-insoluble but ethanol-soluble Zein to encompass doxorubicin (DOX)-loaded mesoporous hollow MnO (HMnO). The conditions and capacity of HMnO to generate reactive oxygen species (ROS) were assayed. Mechanical examinations of Zein-HMnO@DOX were performed to evaluate its potential as the embolic agent. In vitro experiments were carried out to evaluate the effect of Zein-HMnO@DOX on HCC. The subcutaneous HCC mouse model and rabbit VX2 HCC model were established to investigate its anti-tumor and anti-metastasis efficacy and explore its potential anti-tumor mechanism.

Findings: The high adhesion and crosslinking of Zein with HMnO@DOX impart Zein-HMnO@DOX with strong mechanical strength to resist deformation and wash-off. Zein gelation and HMnO decomposition in response to water and acidic tumor microenvironment, respectively, enable continuous DOX release and Fenton-like reaction for reactive oxygen species (ROS) production and O release to execute ROS-enhanced TACE. Consequently, Zein-based embolic agents outperform clinically-used lipiodol to significantly inhibit orthotopic HCC growth. More significantly, O release down-regulates hypoxia inducible factor (HIF-1α), vascular endothelial growth factor (VEGF) and glucose transporter protein 1 (GLUT1), which thereby re-programmes TACE-aggravated hypoxic and pro-metastatic microenvironments to repress HCC metastasis towards lung. Mechanistic explorations uncover that such Zein-based TACE agents disrupt oxidative stress, angiogenesis and glycometabolism pathways to inhibit HCC progression.

Interpretation: This innovative work not only provides a new TACE agent for HCC, but also establishes a new strategy to ameliorate TACE-aggravated hypoxia and metastasis motivation against clinically-common HCC metastasis after TACE operation.

Funding: Excellent Young Science Fund for National Natural Science Foundation of China (82022033); National Natural Science Foundation of China (Grant No. 82373086, 82102761); Major scientific and technological innovation project of Wenzhou Science and Technology Bureau (Grant No. ZY2021009); Shanghai Young Top-Notch Talent.

References

Petrillo M, Patella F, Pesapane F, Suter M, Ierardi A, Angileri S . Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments. Future Oncol. 2018; 14(28):2957-2967. DOI: 10.2217/fon-2017-0739. View

Bzeizi K, Arabi M, Jamshidi N, Albenmousa A, Sanai F, Al-Hamoudi W . Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021; 13(24). PMC: 8699068. DOI: 10.3390/cancers13246172. View

Chang C, Dinh T, Lee Y, Wang F, Sung Y, Yu P . Nanoparticle Delivery of MnO and Antiangiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma. ACS Appl Mater Interfaces. 2020; 12(40):44407-44419. DOI: 10.1021/acsami.0c08473. View

Lo C, Ngan H, Tso W, Liu C, Lam C, Poon R . Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35(5):1164-71. DOI: 10.1053/jhep.2002.33156. View

Zhang Y, Wang T, Dong X, Zhu C, Peng Q, Liu C . Salivary Amylase-Responsive Buccal Tablets Wipe Out Chemotherapy-Rooted Refractory Oral Mucositis. Adv Sci (Weinh). 2024; 11(11):e2308439. PMC: 10962474. DOI: 10.1002/advs.202308439. View

Fang C, Xiao G, Wang T, Song L, Peng B, Xu B . Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy. Research (Wash D C). 2023; 6:0108. PMC: 10079287. DOI: 10.34133/research.0108. View

Liu Q, Zhang W, Jiao R, Lv Z, Lin X, Xiao Y . Rational Nanomedicine Design Enhances Clinically Physical Treatment-Inspired or Combined Immunotherapy. Adv Sci (Weinh). 2022; 9(29):e2203921. PMC: 9561875. DOI: 10.1002/advs.202203921. View

Zhang K, Fang Y, He Y, Yin H, Guan X, Pu Y . Extravascular gelation shrinkage-derived internal stress enables tumor starvation therapy with suppressed metastasis and recurrence. Nat Commun. 2019; 10(1):5380. PMC: 6879564. DOI: 10.1038/s41467-019-13115-3. View

Landry J, Moureaux T . Distribution and amino acid composition of protein groups located in different histological parts of maize grain. J Agric Food Chem. 1980; 28(6):1186-91. DOI: 10.1021/jf60232a042. View

10.

Medavaram S, Zhang Y . Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 2018; 7:17. PMC: 6076403. DOI: 10.1186/s40164-018-0109-6. View

11.

Pieper C, Meyer C, Vollmar B, Hauenstein K, Schild H, Wilhelm K . Temporary arterial embolization of liver parenchyma with degradable starch microspheres (EmboCept®S) in a swine model. Cardiovasc Intervent Radiol. 2014; 38(2):435-41. DOI: 10.1007/s00270-014-0966-2. View

12.

Shen Y, Arbman G, Olsson B, Sun X . Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis. Int J Biol Markers. 2011; 26(3):166-72. DOI: 10.5301/JBM.2011.8550. View

13.

Chiu D, Tse A, Xu I, Cui J, Lai R, Li L . Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun. 2017; 8(1):517. PMC: 5593860. DOI: 10.1038/s41467-017-00530-7. View

14.

Vasudevan S, Mehta A, Sharma S, Sharma A . Expression of glucose transporter 1 () - Clinicopathological associations and survival in an Indian cohort of colorectal cancer patients. J Cancer Res Ther. 2022; 18(3):650-655. DOI: 10.4103/jcrt.jcrt_42_21. View

15.

Younes M, Lechago L, Lechago J . Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res. 1996; 2(7):1151-4. View

16.

Li X, Wang Y, Shi Q, Zhen N, Xue J, Liu J . Zein-Based Nanomedicines for Synergistic Chemodynamic/Photodynamic Therapy. ACS Omega. 2022; 7(33):29256-29265. PMC: 9404477. DOI: 10.1021/acsomega.2c03404. View

17.

Pang L, Ng K, Liu J, Yeung W, Zhu J, Chiu T . Plasmacytoid dendritic cells recruited by HIF-1α/eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma. Cancer Lett. 2021; 522:80-92. DOI: 10.1016/j.canlet.2021.09.022. View

18.

Wang T, Zhang X, Xu Y, Xu Y, Zhang Y, Zhang K . Emerging nanobiotechnology-encoded relaxation tuning establishes new MRI modes to localize, monitor and predict diseases. J Mater Chem B. 2022; 10(37):7361-7383. DOI: 10.1039/d2tb00600f. View

19.

Tsurusaki M, Murakami T . Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer. 2015; 4(3):165-75. PMC: 4608659. DOI: 10.1159/000367739. View

20.

Duran-Saenz N, Serrano-Puente A, Gallegos-Flores P, Mendoza-Almanza B, Esparza-Ibarra E, Godina-Gonzalez S . Platelet Membrane: An Outstanding Factor in Cancer Metastasis. Membranes (Basel). 2022; 12(2). PMC: 8875259. DOI: 10.3390/membranes12020182. View